Physician profile
Devin Watts
NPI 1316627888
$600.94
in general payments reported to CMS, 2019-2025
18 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.01 · 2024: $406 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.08 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $97.74 | 2024-2025 | Rexulti, Abilify Maintena |
| Gilead Sciences, INC. | $62.25 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $42.37 | 2024-2025 | Cobenfy |
| Sanofi-Aventis U.S. LLC | $36.61 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $30.74 | 2024-2025 | Fanapt, Hetlioz |
| Amgen INC. | $26.54 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $21.51 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.44 | 2025 | Caplyta |
| Alkermes, INC. | $20.43 | 2024 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $18.72 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $17.59 | 2024 | Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $17.14 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.07 | 2025 | Qelbree |
| Novo Nordisk INC | $14.37 | 2024 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.26 | 2025 | Jardiance |
| Hologic Sales and Service, LLC | $13.82 | 2024 | Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $13.26 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.